A male patient in seventh decade presented to
emergency with obstructed umbilical hernia that got spontaneously reduced. He
was well controlled diabetic on Injection insulin. There was history of heavy
tobacco use for over 3 decades. During work up for elective laparoscopic
umbilical hernia repair, abdominal CT scan was performed which revealed a large
mass lesion in left hepatic lobe. A subsequent triple phase contrast enhanced
MRI scan showed 7 x 5 cm lesion in segment 2, 3 & 4 of the liver that
showed initial rim enhancement and then progressive and centripetal enhancement
after the administration of intravenous contrast material with associated
capsular retraction (Figure 1).
Figure 1. Triple phase MR scan of liver
Based on characteristic MRI scan findings, a diagnosis
of IHC was made.
Diagnostic work up was completed by HRCT chest and
estimation of tumor markers – serum CA 19-9, CEA and AFP all of which were in
specified normal range.
At laparotomy, the liver was non cirrhotic and there
was a large tumor in segment 2, 3, & 4. Anatomic left hepatectomy with designated
lymph node dissection was performed(Figure 2). The postoperative period was uncomplicated
and the patient was discharged on 7th day after surgery. The biopsy
was confirmatory for IHC (small duct type) pT2N0.
Figure 3. Left hepatectomy specimen
Intrahepatic
Cholangiocarcinoma
Arising from bile duct epithelium proximal to second
order biliary radicals, IHC is the second most primary hepatic cancer after
hepatocellular carcinoma.1 Tumors arising from within hepatic
parenchyma and secondarily involving extrahepatic biliary tree are classifies
as IHC (c.f. hilar cholangiocarcinoma which arises from main hepatic ducts or
hepatic confluence).1
The incidence of IHC is increasing worldwide.2 A
recent systematic review of 57 studies (4756 patients) reported that median age
of IHC patients ranged from 49-67 years and 57% were males.3 Another
large retrospective single centre study reported that heavy tobacco use and
diabetes mellitus were particularly prevalent in these patients.1
Presentation: Intrahepatic cholangiocarcinoma
is usually asymptomatic with majority of tumors being diagnosed during
investigations for non specific symptoms such as weight loss, fatigue or
abdominal pain or unrelated abdominal conditions. Some patients though would be
diagnosed with tumor related symptoms e.g. jaundice.4
Imaging: On triple phase contrast
enhanced abdominal CT scan, IHC shows early arterial peripheral enhancement
with gradual filling towards the centre of the lesion.1, 4 At MRI ,
IHC are generally hypointense on T1-weighted images and hyperintense on T2 –
weighted images. Other characteristic features have already been described.
Tumor
markers: Preoperative
CA 19-9 is raised in about 90% patients. Preoperative tumor marker levels of CA
19-9 and CEA have been shown to have prognostic value. In a recent study of 588
patients, 5 year overall (54.5%) survival was significantly better among
patients with low CA 19-9 and CEA.5
Surgery: All medically fit
patients with IHC localized to the liver are candidates for surgery which entails
major hepatectomy and lymphadenectomy. A
recent multicenter study has reported that patients who underwent liver
resection with lymphadenectomy had better 3 & 5 year survival and disease
free survival compared to patients who underwent liver resection without
lymphadenectomy. 6
Resection
margin: Liver
resection with 'wide' resection margin of at ≥ 10 mm is shown to be associated
with favourable outcomes particularly in patients with node negative disease
and for mass forming type of IHC.7
Lymphadenectomy: The Liver Cancer Surgery
Group of Japan proposed that 3 group of lymph nodes as draining nodes for IHC 8
Group 1 – Nodes in hepatoduodenal
ligament. When the tumor is located in left lobe, lesser curvature nodes are
included in group 1
Group 2 – Nodes along common hepatic
artery, left gastric artery, celiac trunk and on posterior surface of
pancreatic
Group 3 – Para aortic nodes
In HPB centres in Japan, group 1 & 2 lymph nodes
are commonly dissected. A recent study
has reported that the rate of lymph node metastasis (LNM) was high across all T
categories and that 1 in 5 patients with T1 disease have LNM.9
For optimal
staging 8th edition of AJCC recommends to harvest at least 6
locoregional nodes
Expanding
boundaries of resection: Portal vein embolization (PVE) is indicated for safe liver
resection if the remnant liver volume is likely to less than 30-40%. ALPPS may
be a valuable adjunct to achieve R0 resection in locally advanced IHC where
remnant liver volume remains inadequate after PVE. A multicenter study
involving 102 patients with advanced IHC suggests that ALPPS should be
restricted to patients with single lesions and sufficient future liver remnant
at stage II operation (FLR2) to get most oncological benefit. 10
Current
status of Liver transplantation: For most centres, liver transplantation is
contraindicated for patients with IHC in a cirrhotic liver. However a recent
multicenter study reported a 5 year actuarial survival rate of 65% in cirrhotic
patients with very early IHC defined as ≤ 2 cm.11,
A recent systematic review of 57 studies (4756
patients) reported that the median survival was 28 (range 9 – 53) months and
overall survival was 30% (5-56%). Adverse prognostic factors included large
tumor size, multiple tumors, LNM and vascular invasion.3
References
1.
Endo I, Gonen M, Yopp A et al.
Intrahepatic Cholangiocarcinoma. Ann Surg 2008;248: 84-96
2.
Mazzaferro V, Gorgen V, Roayaie
S. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J
Hepatol;2020:72:364-77
3.
Mavros MN, Economopoulos KP,
Alexiou VG et al. Treatment and prognosis for patients with intrahepatic
cholangiocarcinoma: Systematic review and meta –analysis. JAMA Surg; 149:565-74
4.
Umberto Cillo, Constatino
Fondevilla, Matteo Donadon et al. Surgery for cholangiocarcinoma. Liver Int;
143:143-55
5.
Moro A, Mehta R, Sahara K et
al. The impact of preoperative CA 19-9 and CEA on outcomes of patients with
intrahepatic cholangiocarcinoma. Ann Surg Oncol 2020 doi:
10/1245/s10434-020-08350-8
6.
Yoh T, Cauchy F, Le Roy B et
al. Prognostic value of lymphadenectomy for long term outcomes in node negative
intrahepatic cholangiocarcinoma: A multicentre study. Surgery 2019;166(6):975-982
7.
Watanabe Y, Matsuyama Y, Izumi
N et al. Effect of surgical margin width after R0 resection after intrahepatic
cholangiocarcinoma: A nationwide survey of liver cancer study group of Japan.
Surgery 2020 doi 10.1016/j.surg.2019.12.009
8.
Uenishi T, Yamamoto T, Takemura
S et al. Surgical treatment for intrahepatic cholangiocarcinoma. Clin J
Gastroenterol; 7:87-93
9.
Zhang XF, Chakedis J, Bagante F
et al. Trends in use of lymphadenectomy in surgery with curative intent for
intrahepatic cholangiocarcinoma. Br J Surg 2018; 105:857-866.
10.
Li J, Moustafa M, Lineckar M et
al. ALPPS for locally advanced intrahepatic cholangiocarcinoma: Did aggressive
surgery lead to oncological benefit? An international multicentre study. Ann
Surg Oncol 2020doi: 10.1245/s10434-019-08192-z
11.
Sapisochin G, Facciuto M, Rubbia‐Brandt L, et al. Liver transplantation for "very early" intrahepatic
cholangiocarcinoma: international retrospective study supporting a prospective
assessment. Hepatology. 2016;64:1178–1188
Authors:
Dr Nitin Vashistha, MS, FIAGES, FACS
Dr Dinesh Singhal, MS, FACS, DNB (Surg Gastro)
Department of Surgical Gastroenterology,
Max Super Speciality Hospital, Saket, New Delhi, India
E mail: gi.cancer.india@gmail.com
Max Super Speciality Hospital, Saket, New Delhi, India
E mail: gi.cancer.india@gmail.com